FBR & Co reissued their outperform rating on shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) in a report issued on Wednesday. FBR & Co currently has a $16.00 price target on the biotechnology company’s stock.

A number of other brokerages have also recently issued reports on CNAT. Zacks Investment Research cut Conatus Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, February 21st. SunTrust Banks, Inc. restated a buy rating and issued a $26.00 price objective (up from $17.00) on shares of Conatus Pharmaceuticals in a research note on Friday, December 23rd. HC Wainwright boosted their price objective on Conatus Pharmaceuticals from $9.00 to $18.00 and gave the company a buy rating in a research note on Tuesday, December 20th. Finally, Stifel Nicolaus boosted their price objective on Conatus Pharmaceuticals from $5.00 to $7.00 and gave the company a buy rating in a research note on Tuesday, December 20th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $13.25.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 4.73 on Wednesday. The firm’s market capitalization is $119.07 million. The stock has a 50 day moving average of $4.77 and a 200-day moving average of $3.16. Conatus Pharmaceuticals has a 1-year low of $1.45 and a 1-year high of $6.30.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.09. During the same period in the prior year, the firm earned ($0.30) EPS. On average, equities analysts expect that Conatus Pharmaceuticals will post ($0.91) earnings per share for the current year.

Your IP Address:

A number of large investors have recently made changes to their positions in CNAT. Renaissance Technologies LLC boosted its position in shares of Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 121,100 shares during the period. United Capital Financial Advisers LLC boosted its position in shares of Conatus Pharmaceuticals by 5.7% in the fourth quarter. United Capital Financial Advisers LLC now owns 154,578 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 8,369 shares during the period. Courage Capital Management LLC bought a new position in shares of Conatus Pharmaceuticals during the third quarter valued at about $200,000. Ellington Management Group LLC bought a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at about $154,000. Finally, ING Groep NV bought a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at about $110,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.